Initial Treatment Recommendations for Hypertension

Blood Pressure Thresholds for Initiating Pharmacotherapy

The American Heart Association recommends starting pharmacological treatment immediately for patients with confirmed blood pressure ≥140/90 mmHg 1
The American College of Cardiology recommends starting treatment at blood pressure 130-139/80-89 mmHg in high-risk patients with existing cardiovascular disease, diabetes, chronic kidney disease, or target organ damage 2, 1

The American Heart Association recommends thiazide/thiazide-like diuretics, ACE inhibitors or ARBs, and long-acting dihydropyridine calcium channel blockers as first-line medication classes for hypertension treatment 2, 1
The American College of Cardiology recommends against using beta-blockers as first-line therapy, except for specific cardiac indications, due to their lower effectiveness in stroke prevention 2, 3

The American Heart Association recommends starting with combination therapy if blood pressure is ≥150/90 mmHg or if the patient has stage 2 hypertension 2, 4
The American College of Cardiology recommends using two first-line agents from different classes, preferably as a single-pill combination, for patients who require combination therapy 2, 1, 5

The American Heart Association recommends initial therapy with a thiazide-type diuretic or calcium channel blocker for black patients with hypertension 2, 3
The American College of Cardiology recommends using ACE inhibitors or ARBs as first-line therapy for patients with chronic kidney disease or albuminuria 4

The American Heart Association recommends a general target blood pressure of <130/80 mmHg for most adults <65 years 2, 4
The American College of Cardiology recommends a systolic blood pressure target of <130 mmHg for adults ≥65 years, if tolerated 2

The American Heart Association recommends against underdosing medications before adding additional agents, and instead recommends titrating to the maximum tolerated dose first 4, 6
The American College of Cardiology recommends monitoring potassium levels when using ACE inhibitors or ARBs, and checking within 7-14 days of initiation or dose change 4

The American Heart Association recommends monthly follow-up after initiation or medication changes until blood pressure target is achieved 1, 4
The American College of Cardiology recommends home blood pressure monitoring with a target of <135/85 mmHg 4, 5

The American College of Cardiology recommends initial therapy with a thiazide-type diuretic, an ACE inhibitor/ARB, or a long-acting calcium channel blocker, with specific selection based on patient race, comorbidities, and blood pressure severity 7, 8, 9
For black adults without heart failure or chronic kidney disease, the American College of Cardiology recommends starting with either a thiazide-type diuretic or a calcium channel blocker, as these classes are more effective as monotherapy in this population 7, 9
The American Diabetes Association recommends using ACE inhibitors or ARBs as first-line therapy in patients with diabetes and albuminuria, and any of the four first-line classes (thiazide diuretic, ACE inhibitor, ARB, or calcium channel blocker) if no albuminuria is present 10
The American Heart Association recommends using beta-blockers as the preferred antihypertensive agents in patients with thoracic aortic disease 7

The European Society of Cardiology recommends using single-pill combination therapy when possible to improve medication adherence, with preferred two-drug combinations including thiazide diuretic + ACE inhibitor or ARB, calcium channel blocker + ACE inhibitor or ARB, and calcium channel blocker + thiazide diuretic 8, 10, 11

The American College of Cardiology recommends starting at an appropriate initial dose and titrating upward, with specific dosing strategies for lisinopril, chlorthalidone, hydrochlorothiazide, and amlodipine 7, 9

The American Diabetes Association recommends avoiding the use of beta-blockers as first-line therapy without specific cardiac indication, as they are less effective for stroke prevention 10
The American Heart Association recommends addressing medication adherence barriers, such as cost and side effects, which are common reasons for treatment failure in resistant hypertension 10